Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

107.62USD
11:26am EDT
Price Change (% chg)

$0.58 (+0.54%)
Prev Close
$107.04
Open
$108.00
Day's High
$108.18
Day's Low
$107.27
Volume
690,314
Avg. Vol
2,182,618
52-wk High
$108.77
52-wk Low
$86.09

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.58
Market Cap (Mil.): $301,883.59
Shares Outstanding (Mil.): 2,820.29
Dividend: 0.70
Yield (%): 2.62

Financials

  JNJ.N Industry Sector
P/E (TTM): -- 32.70 33.67
EPS (TTM): -- -- --
ROI: -- 18.12 17.39
ROE: -- 18.79 18.21
Search Stocks

INDIA PRESS-Johnson & Johnson may buy electrolyte drink ORS-L for 7 bln rupees - Times of India

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

29 Oct 2014

NORDIC STOCKS - Factors to watch on Oct 24

OSLO, Oct 24 - The following stocks may be affected by newspaper reports and other factors on Friday:

24 Oct 2014

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

NEW YORK/DALLAS - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopedics unit were defective.

23 Oct 2014

UPDATE 2-Johnson & Johnson's DePuy wins first trial over Pinnacle hips

(Rewrites throughout, adds trial background and plaintiffs' lawyer quote, adds Dallas dateline)

23 Oct 2014

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

NEW YORK, Oct 23 - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopaedics unit were defective.

23 Oct 2014

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

22 Oct 2014

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON, Oct 22 - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

22 Oct 2014

J&J and Bavarian Nordic expand production of an Ebola vaccine program

- Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

22 Oct 2014

J&J and Bavarian Nordic expand production of an Ebola vaccine program

Oct 22 - Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

22 Oct 2014

Jury deliberations begin in first trial over DePuy's Pinnacle hips

- A lawyer for a Montana woman on Tuesday urged jurors in a U.S. court to find Johnson & Johnson's DePuy Orthopedics unit liable for failing to warn patients that metal-on-metal Pinnacle hip implants were defective at the close of the first trial over the device.

21 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks